Mettler-Toledo International (MTD) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
6 Nov, 2026Executive summary
Improving demand, higher sales volume and strategic execution supported broad-based Q3 growth, led by Asia/Rest of World.
Financial highlights
Q3 net sales rose 6% to $1,094.3M; local-currency growth was 6%.
Adjusted operating profit increased 8% to $333.5M; adjusted operating margin expanded 40 bps to 30.5%.
Adjusted EPS rose 13% to $12.57 from $11.15; reported diluted EPS was $12.29 versus $10.57.
9M net sales rose 6% to $3,068.7M; adjusted EPS increased 12% to $32.91.
Outlook and guidance
Q4 2026 local-currency sales growth is forecast at ~5%; adjusted EPS guidance is $14.84–$15.04, up 11%–13%.
FY2026 local-currency sales growth guidance is ~5%; adjusted EPS guidance rose to $47.70–$47.90, up ~12%.
2027 local-currency sales are forecast to grow ~5%; adjusted EPS is guided to $52.50–$53.50, up 10%–12%.
2027 free cash flow and share repurchases are each expected to be ~$950M; divisional sales outlook ranges from low-single-digit Food Retail growth to mid- to high-single-digit Lab growth.
Latest events from Mettler-Toledo International
- Long-term goals: >6% sales growth, >100 bps margin expansion and mid-teens adjusted EPS growth.MTD
Investor Day 2026 - Q2 2026 delivered 4% sales growth, strong China gains, and raised full-year EPS guidance.MTD
Q2 2026 - Strong Q1 growth, tariff mitigation, and margin initiatives position the business for resilience.MTD
Bank of America 2025 Healthcare Conference - Q4 2025 delivered 8% sales and EPS growth, with a strong outlook for 2026.MTD
Q4 2025 - 2026 guidance targets 4% revenue growth, margin expansion, and full tariff mitigation.MTD
44th Annual J.P. Morgan Healthcare Conference - Q3 2025 delivered strong sales and EPS growth, with innovation and resilience amid tariff headwinds.MTD
Q3 2025 - Q2 sales fell 4% but net earnings rose 4% and full-year EPS guidance was raised.MTD
Q2 2024 - Q1 sales fell 5% to $883.7M, but margin gains and lab growth offset tariff headwinds.MTD
Q1 2025 - Q4 2024 saw double-digit sales and EPS growth, with 2025 guidance tempered by headwinds.MTD
Q4 2024